IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment. Maximum dose reached with no dose-limiting toxicities obser...
Safety Review Committee (SRC) gives Racura Oncology a recommendation to continue the Cardioprotection and Anticancer Synergy (CPACS) study in advanced so...
Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) (“Neurizon” or “the Company”), is pleased to announ...
Amplia and ANZGOG enter into agreement to conduct a clinical study in ovarian cancer evaluating narmafotinib in combination with standard-of-care chemo...
ZEPZELCA® (lurbinectedin), in combination with atezolizumab (Tecentriq®), is approved for use in Australia and Singapore as a first-...
BioOra Limited ("BioOra"), a commercial-stage cell therapy company advancing CAR-T therapies for cancer patients, and Octane Biotech Inc., an Octane Medi...
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endo...
Nelipak® Corporation (“Nelipak”), a leading global provider of healthcare packaging solutions, announced the opening of its new Asi...
Australian company Ferronova announced it has completed enrolment of patients for its two-year trial to progress commercialisation of FerroTrace, a ...
Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel trea...
Stablepharma Limited, specialists in thermostable formulations,announced a development and option-to-license agreement with AFT Pharmaceuticals to ...
Vamorolone is approved and marketed as AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD) in the US, European Union, UK and China New...
The two companies will explore how datma's federated ecosystem can support Rhythm Biosciences' diagnostic development efforts as they shape a future comm...
Antengene Corporation Limited, a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing fir...
© 2026 Biopharma Boardroom. All Rights Reserved.
